Judge Allows Mylan EpiPen Antitrust Case to Advance, Rejecting Dismissal Request

Mylan Pharmaceuticals faces continued litigation over allegations of antitrust activities concerning the price of EpiPen devices. In a recent decision, a Kansas federal judge ruled that the case should proceed to discovery, rejecting Mylan’s request for an early dismissal. The lawsuit accuses Mylan of collaborating with Pfizer to artificially inflate the prices of the widely used emergency allergy medication. This development is a notable step in the ongoing legal battle involving claims of price manipulation by major pharmaceutical stakeholders. More details surrounding this ruling are available here.